Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration

Ferrara, 2004, Vascular endothelial growth factor as a target for anticancer therapy, Oncologist, 9, 2, 10.1634/theoncologist.9-suppl_1-2

Gragoudas, 2004, Pegaptanib for neovascular age-related macular degeneration, N Engl J Med, 351, 2805, 10.1056/NEJMoa042760

Rosenfeld, 2006, Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, 1419, 10.1056/NEJMoa054481

Brown, 2006, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, 355, 1432, 10.1056/NEJMoa062655

Lux, 2007, Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions, Br J Ophthalmol, 91, 1318, 10.1136/bjo.2006.113902

Krebs, 2013, Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration, Br J Ophthalmol, 97, 1443, 10.1136/bjophthalmol-2013-303513

1999, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group, Arch Ophthalmol, 117, 1329, 10.1001/archopht.117.10.1329

Yamashiro, 2012, Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment, Am J Ophthalmol, 154, 125, 10.1016/j.ajo.2012.01.010

Kruger Falk, 2013, Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment, Am J Ophthalmol, 155, 89, 10.1016/j.ajo.2012.06.031

Martin, 2011, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, 364, 1897, 10.1056/NEJMoa1102673

Chakravarthy, 2012, Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial, Ophthalmology, 119, 1399, 10.1016/j.ophtha.2012.04.015

Hikichi, 2012, One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients, Am J Ophthalmol, 154, 117, 10.1016/j.ajo.2011.12.019

Friedlander, 2007, Fibrosis and diseases of the eye, J Clin Invest, 117, 576, 10.1172/JCI31030

Marmor, 1990, Control of subretinal fluid: experimental and clinical studies, Eye (Lond), 4, 340, 10.1038/eye.1990.46

Saito, 2012, Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation, Am J Ophthalmol, 153, 504, 10.1016/j.ajo.2011.08.038

Gharbiya, 2009, Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results, Retina, 29, 740, 10.1097/IAE.0b013e3181a0be1d

Ying, 2013, Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration, Ophthalmology, 120, 122, 10.1016/j.ophtha.2012.07.042